In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Diagnostic performance of quantitative flow ratio from coronary angiography versus fractional flow reserve from computed tomography

Session Assessment of residual risk after percutaneous coronary intervention

Speaker Hiroki Emori

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease: Angiography, Invasive Imaging, FFR
  • Session type : Moderated Posters
  • FP Number : P1252

Authors : H Emori (Wakayama,JP), T Kubo (Wakayama,JP), T Tanigaki (Gifu,JP), Y Kawase (Gifu,JP), Y Shiono (Wakayama,JP), K Shimamura (Wakayama,JP), Y Sobue (Gifu,JP), Y Matsuo (Wakayama,JP), T Hirata (Gifu,JP), H Kitabata (Wakayama,JP), H Ota (Gifu,JP), Y Ino (Wakayama,JP), M Okubo (Gifu,JP), H Matsuo (Gifu,JP), T Akasaka (Wakayama,JP)

H Emori1 , T Kubo1 , T Tanigaki2 , Y Kawase2 , Y Shiono1 , K Shimamura1 , Y Sobue2 , Y Matsuo1 , T Hirata2 , H Kitabata1 , H Ota2 , Y Ino1 , M Okubo2 , H Matsuo2 , T Akasaka1 , 1Wakayama Medical University, Division of cardiovascular medicine - Wakayama - Japan , 2Gifu Heart Center - Gifu - Japan ,


Background:QFR and FFRCTare recently developed, less-invasive techniques for functional assessment of coronary artery disease.  

Objectives:We compared the diagnostic performance between fractional flow reserve derived from computed tomography(FFRCT) and quantitative flow ratio(QFR) derived from coronary angiography, using FFR as the standard reference.

Methods:We measuredFFRCT, QFR and FFR in 152 patients (233 vessels) with stable coronary artery disease.

Results:QFR was highly correlated with FFR (r = 0.78, p < 0.001), while FFRCTwas moderately correlated with FFR (r = 0.63, p < 0.001). Both QFR and FFRCTshowed good agreements with FFR, presenting small values of mean difference and root-mean-squared deviation (FFR -QFR: 0.02 ± 0.09 and FFR -FFRCT: 0.03 ± 0.11). The AUC of QFR was significantly greater than that of 3D-QCA-derived %DS(0.93 vs. 0.78; difference: 0.15; 95% CI: 0.09 to 0.20; p < 0.001). The AUC of FFRCTwas significantly greater than that of CCTA-derived %DS (0.82 vs. 0.70; difference: 0.12; 95% CI: 0.05 to 0.19; p < 0.001). The AUC of QFR was significantly greater than that of FFRCT(0.93 vs. 0.82; difference: 0.11; 95% CI: 0.05 to 0.16; p < 0.001). The sensitivity, specificity, positive predictive value, and negative predictive valueof QFR =0.80 for predicting FFR =0.80 were 90%, 82%, 81%, and 90%, respectively. Those of FFRCT=0.80 for predicting FFR =0.80 were 82%, 70%, 70%, and 82%, respectively. The diagnostic accuracy of QFR =0.80 for predicting FFR =0.80 was 85% [95% confidence interval: 81% to 89%], while that of FFRCT=0.80 for predicting FFR =0.80was 76% [95% confidence interval: 70% to 80%]. 

Conclusions:Both QFR and FFRCTpossessed the ability to accurately evaluate the functional severity of coronary stenosis.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are